Hikma Pharmaceuticals PLC

HIK

GB00B0LCW083

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:02 06/02/2026 pm IST			5-day change	1st Jan Change
1,540.00 ^GBX	-0.77%		+0.72%	-0.65%

05/02	US tech malaise, mining deal flop weigh on FTSE	AN
05/02	UK Stocks-Factors to watch on February 5	RE

Hikma R&D - Innovating analytical research: meet Saras Konar

Published on 07/17/2025 at 09:13 pm IST

Publicnow

HIKMA PHARMACEUTICALS PLC

-0.77%

London, 17 July 2025

Based at our Columbus, OH site, Saras is part of Hikma's R&D team, working at the intersection of science, innovation, and patient impact.

At Hikma, we take pride in our strong commercial, R&D, manufacturing, and distribution capabilities across our markets, driven by a commitment to quality and efficiency.

Discover what a typical day in R&D looks like for Saras.

Attachments

Original document
Permalink

Disclaimer

Hikma Pharmaceuticals plc published this content on July 17, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 17, 2025 at 15:42 UTC.

Latest news about Hikma Pharmaceuticals PLC

05/02	US tech malaise, mining deal flop weigh on FTSE	AN
05/02	UK Stocks-Factors to watch on February 5	RE
05/02	Brookfield Refutes Hikma Pharmaceuticals Takeover Offer Rumors	MT
05/02	Brookfield rules out offer for UK's Hikma	RE
22/01	FTSE 100 edges up as underperforms European peers	AN
19/01	Hikma launches Enoby and Xtrenbo referencing Prolia and Xgeva respectively	RE
17/01	US Supreme Court to hear 'skinny label' patent fight involving Amarin	RE
09/01	Berenberg raises M&S; BofA cuts Barratt Redrow	AN
09/01	Hikma Pharmaceuticals faces tougher path to re-rating
07/01	Berenberg raises Vodafone; Barclays cuts Hikma	AN
07/01	FTSE 100 retreats from high as oil firms fall	AN
07/01	Reckitt proposes GBP1.6 billion special dividend	AN
15/12	FTSE 100 makes headway ahead of likely BoE cut	AN
15/12	London Shares Start Week Higher Ahead of Inflation Data, Monetary Policy Move	MT
15/12	Global markets live: iRobot, Cencora, Franklin Resources, Sanofi, Enel…
15/12	Hikma Pharmaceuticals plc Announces Board Changes, Effective December 15, 2025	CI
15/12	Hikma Pharmaceuticals PLC Announces Riad Mishlawi Step Down as Chief Executive Officer	CI
15/12	FTSE rises as miners lift stocks	AN
15/12	Stocks up ahead of busy week for central banks	AN
15/12	UK's Hikma CEO steps down, chairman takes helm until successor appointed	RE
15/12	Hikma Pharmaceuticals CEO replaced by former CEO after guidance cut	AN
15/12	Hikma Pharmaceuticals CEO Steps Down; Executive Chairman Named Successor	MT
15/12	Hikma CEO exits; DBAY to vote against TT deal	AN
15/12	Hikma CEO Riad Mishlawi steps down	RE
15/12	Hikma's CEO Riad Mishlawi steps down	RE

Chart Hikma Pharmaceuticals PLC

Duration

Period

HIK: Dynamic Chart

Company Profile

Hikma Pharmaceuticals PLC specializes in developing, producing, and selling drugs used in treating cardiovascular diseases, infections, cancers, diabetes, etc. Net sales break down by family of products as follows: - generic injectable products (41.8%); - generic products taken orally (32.8%); - brand name drugs (24.68%); - other (0.8%). Net sales are distributed geographically as follows: the United Kingdom (0.4%), the United States (61.1%), Middle East and North Africa (31.5%) and other (7%).

Employees

9,500

Sector

Pharmaceuticals

Calendar

26/02 - Q4 2025 Earnings Release

More about the company